Cargando…
The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist Therapy
Background: Dual Amylin and Calcitonin Receptor Agonists (DACRAs) are treatment candidates for obesity and type 2 diabetes. Recently, a once-weekly DACRA (KBP-A) showed promise, potentially due to its different exposure profile compared to daily DACRA (KBP). Parathyroid hormone, a G-protein-coupled...
Autores principales: | Sonne, Nina, Larsen, Anna Thorsø, Karsdal, Morten Asser, Henriksen, Kim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599033/ https://www.ncbi.nlm.nih.gov/pubmed/36289629 http://dx.doi.org/10.3390/biomedicines10102365 |
Ejemplares similares
-
The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
por: Larsen, Anna Thorsø, et al.
Publicado: (2021) -
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
por: Sonne, Nina, et al.
Publicado: (2020) -
KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats
por: Andreassen, K.V., et al.
Publicado: (2021) -
Treatment with a dual amylin and calcitonin receptor agonist improves metabolic health in an old, obese, and ovariectomized rat model
por: Katri, Anna, et al.
Publicado: (2021) -
Combining naproxen and a dual amylin and calcitonin receptor agonist improves pain and structural outcomes in the collagen-induced arthritis rat model
por: Katri, Anna, et al.
Publicado: (2019)